Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.” | Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
Emergent BioSolutions eliminates Chief R&D, cuts 93 jobs, saves $40M annually as Narcan sales fell 22% YoY. CEO Papa consolidates R&D and business development for faster capital allocation to biodefense ($168M, +188% YoY), replacing Narcan as growth core.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have

Epic President Sumit Rana shared with company staff on Friday that he plans to step away from Epic for personal reasons. | Epic…

With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake…

In his first earnings call just days after becoming Sarepta Therapeutics | In his first earnings call just days after becoming…

With Bayer’s pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter, analysts…

Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic…